SCHEMBL23144530

SCHEMBL23144530

O=C(CCl)N(Cc1ccccc1)[C@H]1CCCC[C@H]1CO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.46
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
ALDH1A1 P00352 3/20 0.44
PAX8 Q06710 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 2/20 0.44
GLA P06280 1/20 0.44
AGER Q15109 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 1/20 0.44
MITF O75030 1/20 0.44
SLC18A3 Q16572 1/20 0.42
MTNR1A P48039 1/20 0.41
OPRM1 P35372 2/20 0.41
TDP1 Q9NUW8 1/20 0.39
YAP1 P46937 1/20 0.39
TEAD4 Q15561 1/20 0.39
CHRM2 P08172 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23144533 1.00 CTSD (0.46) CTSDNPC1RAB9AALDH1A1PAX8
SCHEMBL23144534 1.00 CTSD (0.46) CTSDNPC1RAB9AALDH1A1PAX8
SCHEMBL5378349 0.88 CTSD (0.48) CTSDALDH1A1SMN1; SMN2HTTAGER
SCHEMBL17314169 0.84 SLC18A3 (0.57) CTSDNPC1RAB9AALDH1A1PAX8
SCHEMBL17314167 0.84 SLC18A3 (0.57) CTSDNPC1RAB9AALDH1A1PAX8
SCHEMBL17314168 0.84 SLC18A3 (0.57) CTSDNPC1RAB9AALDH1A1PAX8
SCHEMBL23144528 0.81 SLC18A3 (0.54) CTSDNPC1RAB9AALDH1A1PAX8
SCHEMBL23175993 0.79 AGER (0.63) NPC1RAB9AALDH1A1PAX8SMN1; SMN2
SCHEMBL21359110 0.79 CTSD (0.50) CTSDALDH1A1AGERMEN1KMT2A
SCHEMBL2936216 0.77 OPRM1 (0.58) CTSDNPC1RAB9AALDH1A1PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220387411-A1 TARGETED AUTOPHAGY CONJUGATES AND METHODS VULCAN BIO CORPORATION 2022-12-08 US disclosed
US-20220387411-A1 TARGETED AUTOPHAGY CONJUGATES AND METHODS VULCAN BIO CORPORATION 2022-12-08 US disclosed
EP-4034557-A1 TARGETED AUTOPHAGY CONJUGATES AND METHODS Frontier Medicines Corporation (US) 2022-08-03 EP disclosed
WO-2021061858-A1 TARGETED AUTOPHAGY CONJUGATES AND METHODS FRONTIER MEDICINES CORPORATION (US) 2021-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387411-A1 TARGETED AUTOPHAGY CONJUGATES AND METHODS ATG7, BECN1, SQSTM1 CTSD 202/4885NPC1 48/4885RAB9A 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.